Sodium-Glucose Transporter 2
"Sodium-Glucose Transporter 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL KIDNEY TUBULES.
| Descriptor ID |
D051297
|
| MeSH Number(s) |
D12.776.157.530.450.625.437.750 D12.776.157.530.500.750.750 D12.776.157.530.937.700 D12.776.543.585.450.625.562.750 D12.776.543.585.500.750.750 D12.776.543.585.937.825
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sodium-Glucose Transporter 2".
Below are MeSH descriptors whose meaning is more specific than "Sodium-Glucose Transporter 2".
This graph shows the total number of publications written about "Sodium-Glucose Transporter 2" by people in this website by year, and whether "Sodium-Glucose Transporter 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sodium-Glucose Transporter 2" by people in Profiles.
-
Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol. 2024 07 15; 23(1):252.
-
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
Jabbour S. Durability of response to dapagliflozin: a review of long-term efficacy and safety. Curr Med Res Opin. 2017 09; 33(9):1685-1696.
-
Fortuna D, McCloskey LJ, Stickle DF. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol. Clin Chim Acta. 2016 Jan 15; 452:138-41.
-
Dardi I, Kouvatsos T, Jabbour SA. SGLT2 inhibitors. Biochem Pharmacol. 2016 Feb 01; 101:27-39.
-
Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med. 2012 Jul; 124(4):62-73.